University of Chicago: Head and Neck Neoplasms trials

The registry lists 25 Head and Neck Neoplasms studies with University of Chicago as lead sponsor. 5 are open to participants now and 8 have results posted.

Early Phase 1 1Phase 1 5Phase 2 17Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After TreatmentRecruitingNCT07179315Phase 2
• Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck CancerRecruitingNCT07065630Phase 2
• Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCCRecruitingNCT06912087Phase 1
• Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck CancerRecruitingNCT05526924Phase 1
• A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck CancerRecruitingNCT05420948Phase 2
• Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior ImmunotherapyTerminatedNCT03463161Phase 2Results posted
• A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay StudyCompletedNCT02841748Phase 2Results posted
• PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT01816984Phase 1/2Results posted
• Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck CancerCompletedNCT01185171Phase 2Results posted
• Everolimus Versus Placebo in Head and Neck CancerTerminatedNCT01111058Phase 2Results posted
• Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and NeckCompletedNCT00519077Phase 2Results posted
• Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck CancerCompletedNCT00468169Phase 2Results posted
• Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)CompletedNCT00117572Phase 3Results posted
• Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck CancerTerminatedNCT06110195Phase 1
• TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck CancersActive, not recruitingNCT05108870Phase 1/2
• The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology CareSuspendedNCT04541381Not applicable
• A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 TherapyWithdrawnNCT03238638Phase 2
• Leg Function and ADL After ALT Reconstruction for Head and Neck CancerCompletedNCT02332161
• A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck CancerCompletedNCT01693718Phase 2
• Feasibility of Imaging in the Treatment of Patients With Advanced Head and Neck CancerCompletedNCT01359267Early Phase 1
• Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck CancerCompletedNCT01187472
• Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer PatientsCompletedNCT01172470Phase 2
• A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and NeckCompletedNCT00203905Phase 2
• ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and NeckCompletedNCT00015964Phase 2
• Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck CancerCompletedNCT00002951Phase 2